ReviewCurrent obesity reports2026
Decoding Adipose Tissue Phenotypic Switching: From Mechanisms to Computational Drug Discovery.
Review in Current obesity reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Activation of Brown Adipocytes by Farnesoid X Receptor Agonist, Obeticholic Acid-A Potential Novel Therapeutic Avenue in the Management of Obesity.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewThis review aims to explore the therapeutic potential of brown adipose tissue (BAT) to combat obesity and associated metabolic disorders by synthesizing the multifactorial influences and underlying mechanisms of BAT whitening and employing computational screening to identify promising candidate molecules for further investigation. RECENT
findingsBAT whitening is characterized by the loss of thermogenic capacity, representing a critical aspect of adipose plasticity. Although diverse physiological and environmental triggers have been identified, the mechanistic interconnections underlying this process remain poorly understood. Emerging evidence supports an integrated view of these factors, and bioinformatic approaches now provide a valuable tool for the preliminary screening of potential intervention candidates. This review synthesizes current understanding on BAT whitening, from influencing factors to mechanistic pathways. Mitochondrial dysfunction appears to be a critical hub that could link diverse triggers to downstream metabolic and functional decline. Through bioinformatic screening, 4-hydroxybenzoic acid (4-HBA) is proposed as a candidate worthy of further study. Future work should prioritize experimental validation to clarify its mechanism and assess its translational potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.